Aptamers

2019 Activity indicators

  • 4 competitive public projects - ISCIII, MINECO.
  • 1 private led project.
  • 5 competitive HR contracts.
  • 1 supervised read thesis.
  • Project evaluators in national institutions: 2 PIs.
  • Project evaluators in European institutions: 1 PI.
  • Member of editorial committees: 1 PI.
  • 1 month's stay at other centres:
    • Chile University.
    • University Hospital of Valencia (Spain).
  • 1 visitor received and 1 month's stay:
  • Republica University (Uruguay).
  • 2 national patents:
    • P201930524 "Aptamers specific for TLR-4 and their uses".
    • P201930524 "FPR2 receptor agonist aptamers".
  • 2 European patents:
    • EP17382610 extended in USA 16/647,368 and EU 18 734 266.2 in 2020"MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells".
    • EP 18 382 888.8 "Specific aptamers against the human protein MNK1 and its use in MNK1 detection method and as a MNK1 inhibitor".

Milestones

  1. Participation in the MADRI+D HealthStar program.
  2. Obtaining of 2 pre-doctoral contracts from the Community of Madrid.
  3. Participation as inventors in a new patent: "FPR2 receptor agonist aptamers and their uses" P201930524. 10th of June 2019 and PCT extension of the patent "Aptamers and their use in the treatment of cancer". PCT/EP2019/083547. 03rd of December 2019.
  4. Defense of Celia Pinto's doctoral thesis entitled: "Anti-tumor effect of an aptamer against protein kinase MNK1b in breast cancer" rated with excellent cum laude.
  5. Collaboration with national and international groups for the development of diagnostic and therapeutic tools.

Bibliometrics

  Articles Accum. FI Mean FI Articles Q1 or Q2 % in Q1 or Q2 Articles D1 % in D1
2015 15 48.9 3.21 11 73 3 20
2016 11 45.6 4.14 7 64 3 27
2017 6 19.4 3.24 5 83 1 17
2018 6 25.6 4.27 4 67 2 33
2019 0 0.00 0.00 0 0 0 0
  38 138.81 3.71 27 71 9 24

* Only original articles, editorials, guidelines and reviews

Networks and alliances